AAAAAA

   
Results: 1-25 |
Results: 25
DRUG-INTERACTIONS OF LIPID-ALTERING DRUGS
Authors: BAYS HE DUJOVNE CA
Citation: He. Bays et Ca. Dujovne, DRUG-INTERACTIONS OF LIPID-ALTERING DRUGS, Drug safety, 19(5), 1998, pp. 355-371
EFFICACY AND SAFETY OF SIMVASTATIN 80 MG DAY IN HYPERCHOLESTEROLEMIC PATIENTS/
Authors: STEIN EA DAVIDSON MH DOBS AS SCHROTT H DUJOVNE CA BAYS H WEISS SR MELINO MR STEPANAVAGE ME MITCHEL YB
Citation: Ea. Stein et al., EFFICACY AND SAFETY OF SIMVASTATIN 80 MG DAY IN HYPERCHOLESTEROLEMIC PATIENTS/, The American journal of cardiology, 82(3), 1998, pp. 311-316
GUIDELINES FOR CLINICAL-EVALUATION, DEVELOPMENT, AND REGULATION OF LIPID-ACTING ANTI-ATHEROSCLEROSIS AGENTS - INTRODUCTION
Authors: DUJOVNE CA
Citation: Ca. Dujovne, GUIDELINES FOR CLINICAL-EVALUATION, DEVELOPMENT, AND REGULATION OF LIPID-ACTING ANTI-ATHEROSCLEROSIS AGENTS - INTRODUCTION, The American journal of cardiology, 81(8A), 1998, pp. 1-1
GUIDELINES FOR CLINICAL-EVALUATION, DEVELOPMENT, AND REGULATION OF LIPID-ACTING ANTI-ATHEROSCLEROSIS AGENTS
Authors: DUJOVNE CA
Citation: Ca. Dujovne, GUIDELINES FOR CLINICAL-EVALUATION, DEVELOPMENT, AND REGULATION OF LIPID-ACTING ANTI-ATHEROSCLEROSIS AGENTS, The American journal of cardiology, 81(8A), 1998, pp. 7-7
NEW LIPID-LOWERING DRUGS AND NEW EFFECTS OF OLD DRUGS
Authors: DUJOVNE CA
Citation: Ca. Dujovne, NEW LIPID-LOWERING DRUGS AND NEW EFFECTS OF OLD DRUGS, Current opinion in lipidology, 8(6), 1997, pp. 362-368
INHIBITING CHOLESTEROL ABSORPTION WITH CP-88,818 (BETA-TIGOGENIN CELLOBIOSIDE TIQUESIDE) - STUDIES IN NORMAL AND HYPERLIPIDEMIC SUBJECTS
Authors: HARRIS WS DUJOVNE CA WINDSOR SL GERROND LLC NEWTON FA GELFAND RA
Citation: Ws. Harris et al., INHIBITING CHOLESTEROL ABSORPTION WITH CP-88,818 (BETA-TIGOGENIN CELLOBIOSIDE TIQUESIDE) - STUDIES IN NORMAL AND HYPERLIPIDEMIC SUBJECTS, Journal of cardiovascular pharmacology, 30(1), 1997, pp. 55-60
CHOLESTEROL-LOWERING EFFICACY OF SIMVASTATIN AT DOSES OF 80 AND 160 MG D IN A NEW LOW SYSTEMIC EXPOSURE FORMULATION/
Authors: STEIN EA DAVIDSON MH DUJOVNE CA INSULL W TOTH P MITCHEL YB MELINO MR TOBERT JA
Citation: Ea. Stein et al., CHOLESTEROL-LOWERING EFFICACY OF SIMVASTATIN AT DOSES OF 80 AND 160 MG D IN A NEW LOW SYSTEMIC EXPOSURE FORMULATION/, Atherosclerosis, 130, 1997, pp. 22-22
THE CLINICAL THERAPEUTIC IMPLICATIONS OF THE SCANDINAVIAN SIMVASTATINSURVIVAL STUDY
Authors: DUJOVNE CA
Citation: Ca. Dujovne, THE CLINICAL THERAPEUTIC IMPLICATIONS OF THE SCANDINAVIAN SIMVASTATINSURVIVAL STUDY, The American journal of cardiology, 79(10), 1997, pp. 1387
THE EFFICACY AND 6-WEEK TOLERABILITY OF SIMVASTATIN 80 AND 160 MG DAY/
Authors: DAVIDSON MH STEIN EA DUJOVNE CA HUNNINGHAKE DB WEISS SR KNOPP RH ILLINGWORTH DR MITCHEL YB MELINO MR ZUPKIS RV DOBRINSKA MR AMIN RD TOBERT JA
Citation: Mh. Davidson et al., THE EFFICACY AND 6-WEEK TOLERABILITY OF SIMVASTATIN 80 AND 160 MG DAY/, The American journal of cardiology, 79(1), 1997, pp. 38-42
CLINICAL PHARMACOLOGICAL CONCEPTS FOR THE RATIONAL SELECTION AND USE OF DRUGS FOR THE MANAGEMENT OF DYSLIPIDEMIA
Authors: DUJOVNE CA MORIARTY PM
Citation: Ca. Dujovne et Pm. Moriarty, CLINICAL PHARMACOLOGICAL CONCEPTS FOR THE RATIONAL SELECTION AND USE OF DRUGS FOR THE MANAGEMENT OF DYSLIPIDEMIA, Clinical therapeutics, 18(3), 1996, pp. 392-410
THE EFFECTS OF COLESTIPOL TABLETS COMPARED WITH COLESTIPOL GRANULES ON PLASMA-CHOLESTEROL AND OTHER LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC PATIENTS
Authors: INSULL W DAVIDSON MH DEMKE DM DUJOVNE CA ECKERT SM GINSBERG D GOLDBERG AC HODIS HN HUGHES TA KANE JP OLIPHANT TH PITT WA SCHROTT HG SPRECHER DL ZAVORAL JH
Citation: W. Insull et al., THE EFFECTS OF COLESTIPOL TABLETS COMPARED WITH COLESTIPOL GRANULES ON PLASMA-CHOLESTEROL AND OTHER LIPIDS IN MODERATELY HYPERCHOLESTEROLEMIC PATIENTS, Atherosclerosis, 112(2), 1995, pp. 223-235
ENHANCED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL REDUCTION AND COST-EFFECTIVENESS BY LOW-DOSE COLESTIPOL PLUS LOVASTATIN COMBINATION THERAPY
Authors: SCHROTT HG STEIN EA DUJOVNE CA DAVIDSON MH GORIS GB OLIPHANT TH PHILLIPS JC SHAWARYN GG
Citation: Hg. Schrott et al., ENHANCED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL REDUCTION AND COST-EFFECTIVENESS BY LOW-DOSE COLESTIPOL PLUS LOVASTATIN COMBINATION THERAPY, The American journal of cardiology, 75(1), 1995, pp. 34-39
DRUG-INTERACTIONS WITH FIBRIC ACIDS
Authors: LOZADA A DUJOVNE CA
Citation: A. Lozada et Ca. Dujovne, DRUG-INTERACTIONS WITH FIBRIC ACIDS, Pharmacology & therapeutics, 63(2), 1994, pp. 163-176
PSYCHOLOGICAL EFFECTS OF LIPID-LOWERING DRUGS
Authors: HOUSTON BK DUJOVNE CA BABYAK MA
Citation: Bk. Houston et al., PSYCHOLOGICAL EFFECTS OF LIPID-LOWERING DRUGS, Psychosomatic medicine, 56(2), 1994, pp. 165-165
BENEFITS OF ESTROGEN-REPLACEMENT THERAPY ON SERUM-LIPOPROTEINS WITH OR WITHOUT CONCURRENT LIPID-REGULATING DRUGS
Authors: ELSHIEKH RA GERROND LLC HARRIS WS DUJOVNE CA
Citation: Ra. Elshiekh et al., BENEFITS OF ESTROGEN-REPLACEMENT THERAPY ON SERUM-LIPOPROTEINS WITH OR WITHOUT CONCURRENT LIPID-REGULATING DRUGS, Circulation, 90(4), 1994, pp. 460-460
BENEFITS OF ESTROGEN-REPLACEMENT THERAPY ON SERUM-LIPOPROTEINS WITH OR WITHOUT CONCURRENT LIPID-REGULATING DRUGS
Authors: ELSHIEKH RA GERROND LLC HARRIS WS DUJOVNE CA
Citation: Ra. Elshiekh et al., BENEFITS OF ESTROGEN-REPLACEMENT THERAPY ON SERUM-LIPOPROTEINS WITH OR WITHOUT CONCURRENT LIPID-REGULATING DRUGS, Circulation, 90(4), 1994, pp. 460-460
COMPARATIVE EFFECTS OF LOVASTATIN AND NIACIN IN PRIMARY HYPERCHOLESTEROLEMIA - A PROSPECTIVE TRIAL
Authors: ILLINGWOUTH DR STEIN EA MITCHEL YB DUJOVNE CA FROST PH KNOPP RH TUN P ZUPKIS RV GREGUSKI RA
Citation: Dr. Illingwouth et al., COMPARATIVE EFFECTS OF LOVASTATIN AND NIACIN IN PRIMARY HYPERCHOLESTEROLEMIA - A PROSPECTIVE TRIAL, Archives of internal medicine, 154(14), 1994, pp. 1586-1595
FLUVASTATIN ADMINISTRATION AT BEDTIME VERSUS WITH THE EVENING MEAL - A MULTICENTER COMPARISON OF BIOAVAILABILITY, SAFETY, AND EFFICACY
Authors: DUJOVNE CA DAVIDSON MH
Citation: Ca. Dujovne et Mh. Davidson, FLUVASTATIN ADMINISTRATION AT BEDTIME VERSUS WITH THE EVENING MEAL - A MULTICENTER COMPARISON OF BIOAVAILABILITY, SAFETY, AND EFFICACY, The American journal of medicine, 96, 1994, pp. 190000037-190000040
EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS - 2-YEAR EFFICACY AND SAFETY FOLLOW-UP
Authors: BRADFORD RH SHEAR CL CHREMOS AN DUJOVNE CA FRANKLIN FA GRILLO RB HIGGINS J LANGENDORFER A NASH DT POOL JL SCHNAPER H
Citation: Rh. Bradford et al., EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS - 2-YEAR EFFICACY AND SAFETY FOLLOW-UP, The American journal of cardiology, 74(7), 1994, pp. 667-673
COMPARISON OF EFFECTS OF PROBUCOL VERSUS VITAMIN-E ON EX-VIVO OXIDATION SUSCEPTIBILITY OF LIPOPROTEINS IN HYPERLIPOPROTEINEMIA
Authors: DUJOVNE CA HARRIS WS GERROND LLC FAN JY MUZIO F
Citation: Ca. Dujovne et al., COMPARISON OF EFFECTS OF PROBUCOL VERSUS VITAMIN-E ON EX-VIVO OXIDATION SUSCEPTIBILITY OF LIPOPROTEINS IN HYPERLIPOPROTEINEMIA, The American journal of cardiology, 74(1), 1994, pp. 38-42
THE EFFICACY OF INTENSIVE DIETARY THERAPY ALONE OR COMBINED WITH LOVASTATIN IN OUTPATIENTS WITH HYPERCHOLESTEROLEMIA
Authors: HUNNINGHAKE DB STEIN EA DUJOVNE CA HARRIS WS FELDMAN EB MILLER VT TOBERT JA LASKARZEWSKI PM QUITER E HELD J TAYLOR AM HOPPER S LEONARD SB BREWER BK
Citation: Db. Hunninghake et al., THE EFFICACY OF INTENSIVE DIETARY THERAPY ALONE OR COMBINED WITH LOVASTATIN IN OUTPATIENTS WITH HYPERCHOLESTEROLEMIA, The New England journal of medicine, 328(17), 1993, pp. 1213-1219
INCREASED PRODUCTION OF APOLIPOPROTEIN-A-I ASSOCIATED WITH ELEVATED PLASMA-LEVELS OF HIGH-DENSITY-LIPOPROTEINS, APOLIPOPROTEIN-A-I, AND LIPOPROTEIN-A-I IN A PATIENT WITH FAMILIAL HYPERALPHALIPOPROTEINEMIA
Authors: RADER DJ SCHAEFER JR LOHSE P IKEWAKI K THOMAS F HARRIS WA ZECH LA DUJOVNE CA BREWER HB
Citation: Dj. Rader et al., INCREASED PRODUCTION OF APOLIPOPROTEIN-A-I ASSOCIATED WITH ELEVATED PLASMA-LEVELS OF HIGH-DENSITY-LIPOPROTEINS, APOLIPOPROTEIN-A-I, AND LIPOPROTEIN-A-I IN A PATIENT WITH FAMILIAL HYPERALPHALIPOPROTEINEMIA, Metabolism, clinical and experimental, 42(11), 1993, pp. 1429-1434
LOVASTATIN 5-YEAR SAFETY AND EFFICACY STUDY
Authors: DAVIGNON J XHIGNESSE M MAILLOUX H FROHLICH J HAYDEN ML VANETTA H MISHKEL MA MCQUEEN MJ TAN MH WOLFE B NIKKILA E TIKKANEN MJ OJALA JP HELVE E DUJOVNE CA HORNIMAN S GOLDBERG I GINSBERG H GOLDBERG R FARKAS R HUNNINGHAKE D BELL L HELGREN R KNOPP R MCGINNIS B KWITEROVICH P GOLDBERG A BLOOM A MILLER V LAROSA J STOY DB GASPARIS G SCHONFELD G GOLDBERG A ANDERSON C DILLINGHAM M STEINBERG D WITZTUM J KELLY N WEBB H STEIN EA LAMKIN GE LEES RS LEES AM STEIN SW BRENNAN D ILLINGWORTH DR BACON SR GOTTO AM JONES PH FARMER JA PAYTONROSS C FELDMAN EB KUSKE TT DAVIS LC SAMUEL P CHIN B SCHOENFELD BH MARKOWSKI L HAVEL RJ FROST PH TUN P STONE NJ OYER DL RICHARDS L STEIN EA LAZKARZEWSKI P STEINER P TOBERT JA SHAPIRO DR KEEGAN ME GUTWEIN TM PAPPAS F MACHOY B PRAT A GAGNON G DOTY T NYBERG R
Citation: J. Davignon et al., LOVASTATIN 5-YEAR SAFETY AND EFFICACY STUDY, Archives of internal medicine, 153(9), 1993, pp. 1079-1087
COMPARATIVE EFFICACY AND SAFETY OF PRAVASTATIN AND CHOLESTYRAMINE ALONE AND COMBINED IN PATIENTS WITH HYPERCHOLESTEROLEMIA
Authors: KNOPP RH BROWN WV CORDER CN DOBS AS DUJOVNE CA GOLDBERG AC HUNNINGHAKE DB INSULL W MELLIES MJ SMITH DA STEIN EA
Citation: Rh. Knopp et al., COMPARATIVE EFFICACY AND SAFETY OF PRAVASTATIN AND CHOLESTYRAMINE ALONE AND COMBINED IN PATIENTS WITH HYPERCHOLESTEROLEMIA, Archives of internal medicine, 153(11), 1993, pp. 1321-1329
COMPARATIVE EFFECTS OF ATENOLOL VERSUS CELIPROLOL ON SERUM-LIPIDS ANDBLOOD-PRESSURE IN HYPERLIPIDEMIC AND HYPERTENSIVE SUBJECTS
Authors: DUJOVNE CA EFF J FERRARO L GOLDSTEIN RJ GOTTO AM HALL WD HARRIS WS HELD SJ HERD A HUNNINGHAKE DB JOHNSON BF SZTERN MI
Citation: Ca. Dujovne et al., COMPARATIVE EFFECTS OF ATENOLOL VERSUS CELIPROLOL ON SERUM-LIPIDS ANDBLOOD-PRESSURE IN HYPERLIPIDEMIC AND HYPERTENSIVE SUBJECTS, The American journal of cardiology, 72(15), 1993, pp. 1131-1136
Risultati: 1-25 |